Targeting hypoxia in the treatment of small cell lung cancer

Lung Cancer

Volumn 86, Issue 2, 2014, Pages 126-132

  Bryant, J L ^a,b   Meredith, S L ^b   Williams, K J ^b   White, A ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Acidosis; Bioreductive prodrugs; HIF 1 ; Hypoxia; Resistance; Small cell lung cancer; Targeted therapy

Indexed keywords

4 [BIS(2 CHLOROETHYL)OXIDOAMINO]PHENYLALANINE; ALVESPIMYCIN; DIGOXIN; FIRTECAN PEGOL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PRODRUG; RADIOSENSITIZING AGENT; TOPOTECAN; ANTINEOPLASTIC AGENT;

ACIDOSIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CELL DEATH; CELL HYPOXIA; HUMAN; HYPOXIA; HYPOXIC CELL; NONHUMAN; REVIEW; SMALL CELL LUNG CANCER; TREATMENT RESPONSE; TUMOR CELL; UNFOLDED PROTEIN RESPONSE; ANIMAL; ANOXIA; LUNG NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY; SMALL CELL LUNG CARCINOMA;

ANIMALS; ANOXIA; ANTINEOPLASTIC AGENTS; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; SMALL CELL LUNG CARCINOMA;

EID: 84908396140     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.08.003     Document Type: Review

References (84)

1. Powell H.A., Tata L.J., Baldwin D.R., Potter V.A., Stanley R.A., Khakwani A., et al. Treatment decisions and survival for people with small-cell lung cancer. Br J Cancer 2014, 110:908-915.
2. Kurup A., Hanna N.H. Treatment of small cell lung cancer. Crit Rev Oncol Hematol 2004, 52:117-126.
3. Munksgaard Persson M., Johansson M.E., Monsef N., Planck M., Beckman S., Seckl M.J., et al. HIF-2alpha expression is suppressed in SCLC cells, which survive in moderate and severe hypoxia when HIF-1alpha is repressed. Am J Pathol 2012, 180:494-504.
4. Luan Y., Gao C., Miao Y., Li Y., Wang Z., Qiu X. Clinicopathological and prognostic significance of HIF-1alpha and HIF-2alpha expression in small cell lung cancer. Pathol Res Pract 2013, 209:184-189.
5. Polanski R., Hodgkinson C.L., Fusi A., Nonaka D., Priest L., Kelly P., et al. Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer. Clin Cancer Res 2014, 20:926-937.
6. 2 availability on human cancer. Nat Rev Cancer 2008, 8:967-975.
7. Vazquez A., Liu J., Zhou Y., Oltvai Z.N. Catabolic efficiency of aerobic glycolysis: the Warburg effect revisited. BMC Syst Biol 2010, 4:58.
8. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
9. Zhao Y., Butler E.B., Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis 2013, 4:e532.
10. Ioannou M., Papamichali R., Kouvaras E., Mylonis I., Vageli D., Kerenidou T., et al. Hypoxia inducible factor-1 alpha and vascular endothelial growth factor in biopsies of small cell lung carcinoma. Lung 2009, 187:321-329.
11. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
12. Graeber T.G., Osmanian C., Jacks T., Housman D.E., Koch C.J., Lowe S.W., et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996, 379:88-91.
13. Gutova M., Najbauer J., Gevorgyan A., Metz M.Z., Weng Y., Shih C.C., et al. Identification of uPAR-positive chemoresistant cells in small cell lung cancer. PLoS ONE 2007, 2:e243.
14. Lofstedt T., Jogi A., Sigvardsson M., Gradin K., Poellinger L., Pahlman S., et al. Induction of ID2 expression by hypoxia-inducible factor-1: a role in dedifferentiation of hypoxic neuroblastoma cells. J Biol Chem 2004, 279:39223-39231.
15. Erler J.T., Cawthorne C.J., Williams K.J., Koritzinsky M., Wouters B.G., Wilson C., et al. Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol 2004, 24:2875-2889.
16. Morfoisse F., Kuchnio A., Frainay C., Gomez-Brouchet A., Delisle M.B., Marzi S., et al. Hypoxia induces VEGF-C expression in metastatic tumor cells via a HIF-1alpha-independent translation-mediated mechanism. Cell Rep 2014, 6:155-167.
17. Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., Koos R.D., et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996, 16:4604-4613.
18. Wykoff C.C., Beasley N.J., Watson P.H., Turner K.J., Pastorek J., Sibtain A., et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000, 60:7075-7083.
19. Klagsbrun M., Soker S. VEGF/VPF: the angiogenesis factor found. Curr Biol 1993, 3:699-702.
20. Zhan P., Wang J., Lv X.J., Wang Q., Qiu L.X., Lin X.Q., et al. Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol 2009, 4:1094-1103.
21. Ilie M., Mazure N.M., Hofman V., Ammadi R.E., Ortholan C., Bonnetaud C., et al. High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer. Br J Cancer 2010, 102:1627-1635.
22. Holthusen H. Beiträge zur Biologie der Strahlenwirkung. Pflüg Arch Ges Physiol 1921, 187.
23. Thomlinson R.H., Gray L.H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955, 9:539-549.
24. Adamski J., Price A., Dive C., Makin G. Hypoxia-induced cytotoxic drug resistance in osteosarcoma is independent of HIF-1Alpha. PLOS ONE 2013, 8:e65304.
25. Brown L.M., Cowen R.L., Debray C., Eustace A., Erler J.T., Sheppard F.C., et al. Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1. Mol Pharmacol 2006, 69:411-418.
26. Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol 2007, 25:4066-4074.
27. Moulder J.E., Rockwell S. Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev 1987, 5:313-341.
28. Roberts D.L., Williams K.J., Cowen R.L., Barathova M., Eustace A.J., Brittain-Dissont S., et al. Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells. Br J Cancer 2009, 101:1290-1297.
29. Song X., Liu X., Chi W., Liu Y., Wei L., Wang X., et al. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. Cancer Chemother Pharmacol 2006, 58:776-784.
30. Brown J.M. Tumor hypoxia in cancer therapy. Methods Enzymol 2007, 435:297-321.
31. Hay J., Shahzeidi S., Laurent G. Mechanisms of bleomycin-induced lung damage. Arch Toxicol 1991, 65:81-94.
32. Del Mastro L., Gennari A., Donati S. Chemotherapy of non-small-cell lung cancer: role of erythropoietin in the management of anemia. Ann Oncol 1999, 10(Suppl. 5):S91-S94.
33. Wilson W.R., Hay M.P. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011, 11:393-410.
34. Connors T.A., Whisson M.E. Cure of mice bearing advanced plasma cell tumours with aniline mustard: the relationship between glucuronidase activity and tumour sensitivity. Nature 1966, 210:866-867.
35. Brown J.M., Wilson W.R. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004, 4:437-447.
36. Reddy S.B., Williamson S.K. Tirapazamine: a novel agent targeting hypoxic tumor cells. Expert Opin Investig Drugs 2009, 18:77-87.
37. Guise C.P., Mowday A.M., Ashoorzadeh A., Yuan R., Lin W.H., Wu D.H., et al. Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia. Chin J Cancer 2014, 33:80-86.
38. Ke Q., Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol 2006, 70:1469-1480.
39. Kaya A.O., Gunel N., Benekli M., Akyurek N., Buyukberber S., Tatli H., et al. Hypoxia inducible factor-1 alpha and carbonic anhydrase IX overexpression are associated with poor survival in breast cancer patients. J BUON 2012, 17:663-668.
40. Lee G.W., Go S.I., Cho Y.J., Jeong Y.Y., Kim H.C., Duk Lee J., et al. Hypoxia-inducible factor-1alpha and excision repair cross-complementing 1 in patients with small cell lung cancer who received front-line platinum-based chemotherapy: a retrospective study. J Thorac Oncol 2012, 7:528-534.
41. Chen B., Yuping S., Ni J. Rapamycin decreases survivin expression to induce NSCLC cell apoptosis under hypoxia through inhibiting HIF-1alpha induction. Mol Biol Rep 2012, 39:185-191.
42. Ye M.X., Zhao Y.L., Li Y., Miao Q., Li Z.K., Ren X.L., et al. Curcumin reverses cis-platin resistance and promotes human lung adenocarcinoma A549/DDP cell apoptosis through HIF-1alpha and caspase-3 mechanisms. Phytomedicine 2012, 19:779-787.
43. Kamlah F., Eul B.G., Li S., Lang N., Marsh L.M., Seeger W., et al. Intravenous injection of siRNA directed against hypoxia-inducible factors prolongs survival in a Lewis lung carcinoma cancer model. Cancer Gene Ther 2009, 16:195-205.
44. Zhang H., Zhang G., Gonzalez F.J., Park S.M., Cai D. Hypoxia-inducible factor directs POMC gene to mediate hypothalamic glucose sensing and energy balance regulation. PLoS Biol 2011, 9:e1001112.
45. Tu B.P., Weissman J.S. The FAD- and O(2)-dependent reaction cycle of Ero1-mediated oxidative protein folding in the endoplasmic reticulum. Mol Cell 2002, 10:983-994.
46. Wouters B.G., Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 2008, 8:851-864.
47. Fels D.R., Ye J., Segan A.T., Kridel S.J., Spiotto M., Olson M., et al. Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways. Cancer Res 2008, 68:9323-9330.
48. Hu Y., Liu J., Huang H. Recent agents targeting HIF-1alpha for cancer therapy. J Cell Biochem 2013, 114:498-509.
49. Shin D.H., Chun Y.S., Lee D.S., Huang L.E., Park J.W. Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood 2008, 111:3131-3136.
50. Biaoxue R., Xiling J., Shuanying Y., Wei Z., Xiguang C., Jinsui W., et al. Upregulation of Hsp90-beta and annexin A1 correlates with poor survival and lymphatic metastasis in lung cancer patients. J Exp Clin Cancer Res 2012, 31:70.
51. Gallerne C., Prola A., Lemaire C. Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2. Biochim Biophys Acta 2013, 1833:1356-1366.
52. Zanke B.W., Lee C., Arab S., Tannock I.F. Death of tumor cells after intracellular acidification is dependent on stress-activated protein kinases (SAPK/JNK) pathway activation and cannot be inhibited by Bcl-2 expression or interleukin 1beta-converting enzyme inhibition. Cancer Res 1998, 58:2801-2808.
53. Kato Y., Ozawa S., Miyamoto C., Maehata Y., Suzuki A., Maeda T., et al. Acidic extracellular microenvironment and cancer. Cancer Cell Int 2013, 13:89.
54. Chiche J., Ilc K., Laferriere J., Trottier E., Dayan F., Mazure N.M., et al. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res 2009, 69:358-368.
55. Hirschhaeuser F., Sattler U.G., Mueller-Klieser W. Lactate: a metabolic key player in cancer. Cancer Res 2011, 71:6921-6925.
56. Kennedy K.M., Dewhirst M.W. Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation. Future Oncol 2010, 6:127-148.
57. Potter C., Harris A.L. Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle 2004, 3:164-167.
58. van den Beucken T., Koritzinsky M., Niessen H., Dubois L., Savelkouls K., Mujcic H., et al. Hypoxia-induced expression of carbonic anhydrase 9 is dependent on the unfolded protein response. J Biol Chem 2009, 284:24204-24212.
59. Kaluzova M., Pastorekova S., Pastorek J., Kaluz S. P53 tumour suppressor modulates transcription of the TATA-less gene coding for the tumour-associated carbonic anhydrase MN/CA IX in MaTu cells. Biochim Biophys Acta 2000, 1491:20-26.
60. Meuwissen R., Berns A. Mouse models for human lung cancer. Genes Dev 2005, 19:643-664.
61. Zavada J., Zavadova Z., Pastorek J., Biesova Z., Jezek J., Velek J. Human tumour-associated cell adhesion protein MN/CA IX: identification of M75 epitope and of the region mediating cell adhesion. Br J Cancer 2000, 82:1808-1813.
62. Fiaschi T., Giannoni E., Taddei M.L., Cirri P., Marini A., Pintus G., et al. Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells. Cell Cycle 2013, 12:1791-1801.
63. Gieling R.G., Babur M., Mamnani L., Burrows N., Telfer B.A., Carta F., et al. Antimetastatic effect of sulfamate carbonic anhydrase IX inhibitors in breast carcinoma xenografts. J Med Chem 2012, 55:5591-5600.
64. Lou Y., McDonald P.C., Oloumi A., Chia S., Ostlund C., Ahmadi A., et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res 2011, 71:3364-3376.
65. Lee H.S., Bae T., Lee J.H., Kim D.G., Oh Y.S., Jang Y., et al. Rational drug repositioning guided by an integrated pharmacological network of protein, disease and drug. BMC Syst Biol 2012, 6:80.
66. Supuran C.T. Inhibition of carbonic anhydrase IX as a novel anticancer mechanism. World J Clin Oncol 2012, 3:98-103.
67. Ivanov S., Liao S.Y., Ivanova A., Danilkovitch-Miagkova A., Tarasova N., Weirich G., et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 2001, 158:905-919.
68. Radvak P., Repic M., Svastova E., Takacova M., Csaderova L., Strnad H., et al. Suppression of carbonic anhydrase IX leads to aberrant focal adhesion and decreased invasion of tumor cells. Oncol Rep 2013, 29:1147-1153.
69. Bryant J.L., Meredith S.L., Gieling R.G., Telfer B.A., Babur M., Supuran C.T., et al. Inhibiting carbonic anhydrase IX targets hypoxic small cell lung cancer cells. American Association for Cancer Research Annual Meeting 2014, Abstract Number 4980.
70. Parks S.K., Chiche J., Pouyssegur J. Disrupting proton dynamics and energy metabolism for cancer therapy. Nat Rev Cancer 2013, 13:611-623.
71. Powers W.E., Tolmach L.J. Demonstration of an anoxic component in a mouse tumor-cell population by in vivo assay of survival following irradiation. Radiology 1964, 83:328-336.
72. Churchill-Davidson I. Oxygenation in radiotherapy of malignant disease of the upper air passages. The oxygen effect of radiotherapy. Proc R Soc Med 1964, 57:635-638.
73. Saunders M., Dische S. Clinical results of hypoxic cell radiosensitisation from hyperbaric oxygen to accelerated radiotherapy, carbogen and nicotinamide. Br J Cancer Suppl 1996, 27:S271-S278.
74. Janssens G.O., Rademakers S.E., Terhaard C.H., Doornaert P.A., Bijl H.P., van den Ende P., et al. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. J Clin Oncol 2012, 30:1777-1783.
75. Guo W., Zhang Y., Chen T., Wang Y., Xue J., Zhang Y., et al. Efficacy of RNAi targeting of pyruvate kinase M2 combined with cisplatin in a lung cancer model. J Cancer Res Clin Oncol 2011, 137:65-72.
76. Higashi S., Hirose T., Takeuchi T., Miyazaki K. Molecular design of a highly selective and strong protein inhibitor against matrix metalloproteinase-2 (MMP-2). J Biol Chem 2013, 288:9066-9076.
77. Comerford K.M., Wallace T.J., Karhausen J., Louis N.A., Montalto M.C., Colgan S.P. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 2002, 62:3387-3394.
78. Greenberger L.M., Horak I.D., Filpula D., Sapra P., Westergaard M., Frydenlund H.F., et al. RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther 2008, 7:3598-3608.
79. Terzuoli E., Puppo M., Rapisarda A., Uranchimeg B., Cao L., Burger A.M., et al. Aminoflavone, a ligand of the aryl hydrocarbon receptor, inhibits HIF-1alpha expression in an AhR-independent fashion. Cancer Res 2010, 70:6837-6848.
80. Kummar S., Raffeld M., Juwara L., Horneffer Y., Strassberger A., Allen D., et al. Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1alpha in advanced solid tumors. Clin Cancer Res 2011, 17:5123-5131.
81. Garrett C.R., Bekaii-Saab T.S., Ryan T., Fisher G.A., Clive S., Kavan P., et al. Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer. Cancer 2013, 119:4223-4230.
82. Zhang H., Qian D.Z., Tan Y.S., Lee K., Gao P., Ren Y.R., et al. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci U S A 2008, 105:19579-19586.
83. Koh M.Y., Spivak-Kroizman T., Venturini S., Welsh S., Williams R.R., Kirkpatrick D.L., et al. Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Mol Cancer Ther 2008, 7:90-100.
84. Jhaveri K., Miller K., Rosen L., Schneider B., Chap L., Hannah A., et al. A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors. Clin Cancer Res 2012, 18:5090-5098.